Clinical Trials Logo

Clinical Trial Summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).


Clinical Trial Description

This product is being tested for its ability to reduce lateral canthal lines, also known as Crow's Feet. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03655691
Study type Interventional
Source Eirion Therapeutics Inc.
Contact
Status Completed
Phase Phase 2
Start date August 16, 2018
Completion date April 11, 2019

See also
  Status Clinical Trial Phase
Completed NCT02248844 - Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
Completed NCT02195687 - BOTOX® in the Treatment of Crow's Feet Lines in China Phase 3
Completed NCT01951742 - Dose Finding Study In Subjects With Crow's Feet Phase 2
Completed NCT03721016 - MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) Phase 3
Completed NCT03326856 - ET-01 in Subjects With Lateral Canthal Lines Phase 2
Completed NCT04157686 - MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) Phase 3
Completed NCT03923634 - Princess® RICH for the Correction of Fine Lines N/A
Completed NCT03839693 - ET-01 in Subjects With Lateral Canthal Lines, LCL-208 Phase 2
Completed NCT03732833 - MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines Phase 3
Completed NCT00888914 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2
Completed NCT04143854 - Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines Phase 2
Completed NCT01358695 - Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet Phase 2
Completed NCT01124565 - Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Phase 2
Completed NCT00247559 - Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet) Phase 2
Completed NCT01809964 - Clinical Trial to Evaluate ANT-1401 in Crow's Feet Phase 2
Completed NCT03911102 - Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines Phase 2
Completed NCT00968825 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2
Completed NCT04225260 - Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines Phase 3
Completed NCT01064518 - Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Phase 2
Completed NCT00884234 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2